Discover 859 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 859
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
for
Lymphatic Malformation
Location: Birmingham AL, Nashville TN, Little Rock AR,
Sponsor: Protara Therapeutics
Sex: All
Age: 0 - 18
Code: NCT05871970
Phase2, Recruiting
Cord Clamping Among Neonates With Congenital Heart Disease
for
Congenital Heart Disease (CHD)
Location: Birmingham AL, Jackson MS, Nashville TN, Columbia SC,
Sponsor: Carl Backes, MD
Sex: All
Age: 0
Code: NCT06153459
Recruiting
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
for
Neuroblastoma
Location: Birmingham AL, Little Rock AR, Augusta GA,
Sponsor: Giselle Sholler
Sex: All
Age: 1 - 21
Code: NCT05489887
Phase2, Recruiting
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
for
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS),
Location: Birmingham AL, Atlanta GA, Little Rock AR,
Sponsor: Nationwide Children's Hospital
Sex: All
Age: 0 - 17
Code: NCT05267821
Phase2, Phase3, Recruiting
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
for
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Location: Birmingham AL, Akron OH, Aurora CO, Boston MA,
Sponsor: Medicure
Sex: All
Age: 0+
Code: NCT04706013
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
for
Sickle Cell Disease (SCD)
Location: Birmingham AL, Atlanta GA, Memphis TN, Charlotte NC,
Sponsor: University of Rochester
Sex: All
Age: 3 - 20
Code: NCT06941389
Recruiting
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors